Article Sidebar

PDF (Tiếng Việt)
Published: 2023-01-31
Abstract Views: 342
Views PDF (Tiếng Việt): 311
DOI: https://doi.org/10.52852/tcncyh.v162i1.1341
Issue
Vol. 162 No. 1 (2023)
Section
Các bài báo
How to Cite
Khánh Toàn, N. ., & Văn Tờ, T. (2023). 14. Evaluation of first-line pembrolizumab plus double platinum in stage iv non small cell lung cancer. Journal of Medical Research, 162(1), 121-128. https://doi.org/10.52852/tcncyh.v162i1.1341

14. Evaluation of first-line pembrolizumab plus double platinum in stage iv non small cell lung cancer

Nguyen Khanh Toan, Ta Van To

Main Article Content

Abstract

This is a retrospective, descriptive study with longitudinal follow-up aimed to evaluate the efficacy and adverse effects of pembrolizumab plus platinum-doublet chemotherapy in patients with stage IV non-small cell lung cancer. Medical records of patients from 4 hospitals in Vietnam between June 2018 and August 2022 were reviewed. Of 46 patients included in the study, 21 patients (45.7%) were treated with pemetrexed and carboplatin combination pembrolizumab regimen. The median progression-free survival time was 11.0 months (95%CI: 7.3 - 14.6 months). The survival rates of patients after 1 year and 2 years were 80.5% and 45.0%, respectively. The most common adverse effects were anemia and elevated liver enzymes but these were mostly of mild and moderate severity.

Article Details

Keywords

Stage IV non small cell lung cancer, immunotherapy, PD-L1, pembrolizumab

References

1. Globocan 2020. https://www.uicc.org/news/globocan-2020-new-global-cancer-data.
2. Hướng dẫn chẩn đoán và điều trị ung thư phổi không tế bào nhỏ. Quyết định 4825/QĐ-BYT ngày 06/8/2018 của Bộ y tế về việc ban hành tài liệu chuyên môn “Hướng dẫn chẩn đoán và điều trị ung thư phổi không tế bào nhỏˮ.
3. Tạ Văn Tờ, Nguyễn Sơn Lam. Chẩn đoán bệnh học ung thư phổi. Nhà xuất bản Y học 2022.
4. Non small cell lung cancer, Version 4.2022. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
5. RiyazShah, Jason F.Lester. Tyrosine Kinase Inhibitors for the treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations. Clinical Lung Cancer Volume 21, Issue 3, May 2020, Pages e216-e228.
6. Martin Reck, et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer, The New England Journal of Medicine, Med 2016; 375:1823-1833.
7. Leena Gandhi, et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer, The New England Journal of Medicine, Med 2018; 378:2078-2092.
8. Luis Paz-Ares, et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer, The New England Journal of Medicine, Med 2018; 379: 2040-2051.
9. Hidehito Horinouchi, et al. Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study. Clinical Trial, Cancer Sci, 2021 Aug; 112(8): 3255-3265.
10. Ying Cheng, et al. Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407. JTO Clin Res Rep 2021 Sep 25; 2(10): 100225.